Page 13 - கூட்டு ப்ரோக்ர்யாம் நிர்வாகி அலுவலகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function

SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesRobert paineLuisa morales nebredaDebasish roychowdhuryBart lambrechtVan dammePartner therapeutics incFlanders institute of biotechnologyTanner pharma groupUniversity of utahDrug administrationDivision of pulmonary medicineAssociation between hypoxemiaResearch on sargramostimPatient healthInflammation research

CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa

CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa
ghanavisions.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghanavisions.com Daily Mail and Mail on Sunday newspapers.

Ben matoneJeff richardsonKaneka eurogentecKwadwoa koramWalter reed army institute of researchUs department of defenseNational cancer instituteNoguchi memorial institute for medical researchNational institute of allergyPlumbline life sciencesMelinda gates foundationCoalition for epidemic preparedness innovationsInternational vaccine instituteDefense consortiumParker institute for cancer immunotherapyNuclear defense

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

Share this article Share this article PLYMOUTH MEETING, Pa., Feb. 23, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa fever to be conducted in West Africa, where the infection is endemic. INO-4500 is also the first vaccine candidate for Lassa fever to enter human trials.

Greater accraBen matoneJeff richardsonKaneka eurogentecMelanie savilleJ joseph kimKwadwoa koramWalter reed army institute of researchUs department of defenseNational cancer instituteNoguchi memorial institute for medical researchNational institute of allergyNoguchi medical centerPlumbline life sciencesMelinda gates foundationCoalition for epidemic preparedness innovations

Alt-PNT on the Battlefield, Next-Gen Autonomous Combat Vehicles at AUSA Virtual Meeting

Inside GNSS and On Tuesday, March 16, the Next Generation Combat Vehicle: Development in 2021 and Beyond session will include several key waypoints in the development and procurement of new combat vehicles, including the Optionally Manned Fighting Vehicle, and the Campaign of Learning for Robotic Combat Vehicles. With Brigadier General Richard R. Coffman Director, Next Generation Combat Vehicle Cross Functional Team, Army Futures Command; Brigadier General Glenn A. Dean III, Program Executive Officer, Ground Combat Systems, amd Alfred J. Grein, Deputy Executive Director, US Army Combat Capabilities Development Command, Ground Vehicle Systems Center. On Thursday, March 18, a session titled Finding Alternative Ways to Access Assured Position, Navigation, Timing and Space on the Battlefield will discuss alternative ways to access APNT data such as ALTNAV, Vision Based Nav, Anti-Jam, M-Code, etc. Panelists will include CFT partners in the ground, aviation and precisi

United statesVincentf maloneWillie nelsonAlfredj greinRobertl barrie jrUnited states armyProgram executive officeGlobal forceArmy futuresCross functional teamGeneration combat vehicle cross functional teamAssociation of the united states armyUs army combat capabilities developmentGround vehicle systems centerGlobal force nextInside unmanned systems

Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

Press release content from Business Wire. The AP news staff was not involved in its creation. Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing February 18, 2021 GMT EXTON, Pa. (BUSINESS WIRE) Feb 18, 2021 Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing. This effort is part of the company’s ongoing program to develop a cocktail of antibodies targeting spike and non-spike proteins that can serve as a prophylaxis or a treatment for COVID-19. Immunome’s COVID-19 antibody research demonstrates that SARS-CoV-2 “super-responders” who recover from SARS-CoV-2 mount a robust i

South africaUnited statesSouth africanPurnanand sarmaNick changJeffreyp hendersonExchange commissionDefense health agencyNuclear defenseImmunome incSouth african variantAssociate professorMolecular microbiologyWashington university schoolJoint program executive officePrivate securities litigation reform act